APA

Gross G., Roussaki A., Baur S., Wiegand M. & Mescheder A. (19960730). Systemically administered interferon alfa-2a prevents recurrence of condylomata acuminata following CO2-laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial. : Genitourinary medicine.

Chicago

Gross G, Roussaki A, Baur S, Wiegand M and Mescheder A. 19960730. Systemically administered interferon alfa-2a prevents recurrence of condylomata acuminata following CO2-laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial. : Genitourinary medicine.

Harvard

Gross G., Roussaki A., Baur S., Wiegand M. and Mescheder A. (19960730). Systemically administered interferon alfa-2a prevents recurrence of condylomata acuminata following CO2-laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial. : Genitourinary medicine.

MLA

Gross G, Roussaki A, Baur S, Wiegand M and Mescheder A. Systemically administered interferon alfa-2a prevents recurrence of condylomata acuminata following CO2-laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial. : Genitourinary medicine. 19960730.